{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:29:26Z","timestamp":1790695766660,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immune-mediated cytopenias (AIC) are challenging complications following allogeneic hematopoietic stem cell transplantation (HSCT). While broad-acting immunosuppressive agents like corticosteroids are often standard of care, several novel therapies which target specific immunological pathways have recently been developed and provide hope for patients with steroid-refractory courses and may limit long-term toxicity. The successful off-label use of the plasma cell depleting anti-CD38 antibody daratumumab was published in several case reports, suggesting efficacy, i.e., in patients with antibody-mediated AIC refractory to previous B cell depletion. We want to share our experience with two children, whom we treated with daratumumab, including one fatal course with uncontrolled disease. Given the absence of substantial data from HSCT registries or prospective trials, we furthermore provide a critical review of the literature on daratumumab treatment of AIC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentations<\/jats:title>\n                <jats:p>Patient 1 (P1), an 11-year-old girl with lipopolysaccharide-responsive and beige-like anchor protein (LRBA) deficiency who developed immune-mediated thrombocytopenia (AIT) from day +58 after HSCT, showed a complete response to daratumumab after the fourth of six total daratumumab doses. She remains transfusion independent for over a year of follow-up. Previously, her thrombocytopenia was refractory to corticosteroids, rituximab, intravenous immunoglobulins (IVIG), eltrombopag, cyclosporine A, and sirolimus. Patient 2 (P2), a 6-year-old boy with CD40 ligand (CD40L) deficiency, developed both AIT and hemolytic anemia (AIHA) after HSCT on days +58 and +83, respectively, and was also treated with daratumumab after being previously refractory to prednisolone, rituximab, and IVIG. Yet, he did neither respond to daratumumab nor the concomitantly administered methyprednisolone pulse, plasmapheresis, and eculizumab and succumbed due to refractory disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Reviewing the literature on the use of daratumumab for refractory AIC post-HSCT, we consider daratumumab a promising agent for this life-threatening disorder: ten of the twelve patients reached transfusion independency in the literature. However, treatment failures are likely to be underreported. Thus, controlled trials are needed to explore the safety and efficacy of daratumumab in this rare post-HSCT complication.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40348-021-00114-y","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T09:03:19Z","timestamp":1619686999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5689-3125","authenticated-orcid":false,"given":"Lina","family":"Driouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann Josef","family":"Girschick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Strahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte M.","family":"Niemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Speckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"issue":"1","key":"114_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jaci.2015.09.025","volume":"137","author":"L Gamez-Diaz","year":"2016","unstructured":"Gamez-Diaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG, Noriko M et al (2016) The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol. 137(1):223\u2013230. https:\/\/doi.org\/10.1016\/j.jaci.2015.09.025","journal-title":"J Allergy Clin Immunol."},{"issue":"4","key":"114_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","volume":"124","author":"S Jodele","year":"2014","unstructured":"Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, Myers K, Grimley M, Bleesing J, el-Bietar J, Wallace G, Chima RS, Paff Z, Laskin BL (2014) Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 124(4):645\u2013653. https:\/\/doi.org\/10.1182\/blood-2014-03-564997","journal-title":"Blood."},{"issue":"6","key":"114_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/01.md.0000100046.06009.b0","volume":"82","author":"JA Winkelstein","year":"2003","unstructured":"Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME (2003) The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore). 82(6):373\u2013384. https:\/\/doi.org\/10.1097\/01.md.0000100046.06009.b0","journal-title":"Medicine (Baltimore)."},{"issue":"6","key":"114_CR4","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jaci.2018.12.1010","volume":"143","author":"F Ferrua","year":"2019","unstructured":"Ferrua F, Galimberti S, Courteille V, Slatter MA, Booth C, Moshous D, Neven B, Blanche S, Cavazzana M, Laberko A, Shcherbina A, Balashov D, Soncini E, Porta F, al-Mousa H, al-Saud B, al-Dhekri H, Arnaout R, Formankova R, Bertrand Y, Lange A, Smart J, Wolska-Kusnierz B, Aquino VM, Dvorak CC, Fasth A, Fouyssac F, Heilmann C, Hoenig M, Schuetz C, Kele\u010di\u0107 J, Bredius RGM, Lankester AC, Lindemans CA, Suarez F, Sullivan KE, Albert MH, Ka\u0142wak K, Barlogis V, Bhatia M, Bordon V, Czogala W, Alonso L, Dogu F, Gozdzik J, Ikinciogullari A, Kriv\u00e1n G, Ljungman P, Meyts I, Mustillo P, Smith AR, Speckmann C, Sundin M, Keogh SJ, Shaw PJ, Boelens JJ, Schulz AS, Sedlacek P, Veys P, Mahlaoui N, Janda A, Davies EG, Fischer A, Cowan MJ, Gennery AR (2019) Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT\/ESID-IEWP-SCETIDE-PIDTC study. J Allergy Clin Immunol. 143(6):2238\u20132253. https:\/\/doi.org\/10.1016\/j.jaci.2018.12.1010","journal-title":"J Allergy Clin Immunol."},{"key":"114_CR5","doi-asserted-by":"publisher","unstructured":"Even-Or E, Naser Eddin A, Shadur B, Dinur Schejter Y, Najajreh M, Zelig O, Zaidman I, & Stepensky P (2020) Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatr blood & cancer, 67(1):e28010. https:\/\/doi.org\/10.1002\/pbc.28010.","DOI":"10.1002\/pbc.28010"},{"issue":"5","key":"114_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/bloodadvances.2019001215","volume":"4","author":"Y Migdady","year":"2020","unstructured":"Migdady Y, Ediriwickrema A, Jackson RP, Kadi W, Gupta R, Socola F, Arai S, Martin BA (2020) Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review. Blood Adv. 4(5):815\u2013818. https:\/\/doi.org\/10.1182\/bloodadvances.2019001215","journal-title":"Blood Adv."},{"issue":"19","key":"114_CR7","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","volume":"2","author":"C Schuetz","year":"2018","unstructured":"Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M, Shimano K, Tolbert V, Schulz AS, Dvorak CC (2018) Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2(19):2550\u20132553. https:\/\/doi.org\/10.1182\/bloodadvances.2018020883","journal-title":"Blood Adv."},{"key":"114_CR8","doi-asserted-by":"publisher","unstructured":"Blennerhassett R, Sudini L, Gottlieb D, Bhattacharyya A (2019) Post-allogeneic transplant Evans syndrome successfully treated with daratumumab. Br J Haematol 187(2):e48\u2013e51. https:\/\/doi.org\/10.1111\/bjh.16171","DOI":"10.1111\/bjh.16171"},{"issue":"19","key":"114_CR9","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJMoa1807438","volume":"379","author":"CI Chapuy","year":"2018","unstructured":"Chapuy CI, Kaufman RM, Alyea EP, Connors JM (2018) Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med. 379(19):1846\u20131850. https:\/\/doi.org\/10.1056\/NEJMoa1807438","journal-title":"N Engl J Med."},{"issue":"8","key":"114_CR10","doi-asserted-by":"publisher","first-page":"E216","DOI":"10.1002\/ajh.25515","volume":"94","author":"S Bathini","year":"2019","unstructured":"Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, Ruehle K, Kocoglu MH, Badros A, Hardy N, Yared J, Rapoport AP, Fontaine M, Emadi A, el Chaer F, Dahiya S (2019) Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol. 94(8):E216\u2013E2E9. https:\/\/doi.org\/10.1002\/ajh.25515","journal-title":"Am J Hematol."},{"issue":"6","key":"114_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41409-019-0664-4","volume":"55","author":"C Rautenberg","year":"2020","unstructured":"Rautenberg C, Kaivers J, Germing U, Haas R, Ackerstaff S, Hoffmann T, Kobbe G, Schroeder T (2020) Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation. Bone Marrow Transplant. 55(6):1191\u20131193. https:\/\/doi.org\/10.1038\/s41409-019-0664-4","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"114_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/ejh.13343","volume":"104","author":"MQ Salas","year":"2020","unstructured":"Salas MQ, Alahmari A, Lipton JH (2020) Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. Eur J Haematol. 104(2):145\u2013147. https:\/\/doi.org\/10.1111\/ejh.13343","journal-title":"Eur J Haematol."},{"issue":"4","key":"114_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27569","volume":"66","author":"CE Neunert","year":"2019","unstructured":"Neunert CE, Despotovic JM (2019) Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: a critical review of the literature. Pediatr Blood Cancer. 66(4):e27569. https:\/\/doi.org\/10.1002\/pbc.27569","journal-title":"Pediatr Blood Cancer."},{"issue":"4","key":"114_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.bbmt.2017.12.782","volume":"24","author":"MD Kruizinga","year":"2018","unstructured":"Kruizinga MD, van Tol MJD, Bekker V, Netelenbos T, Smiers FJ, Bresters D, Jansen-Hoogendijk AM, van Ostaijen-ten Dam MM, Kollen WJW, Zwaginga JJ, Lankester AC, Bredius RGM (2018) Risk factors, treatment, and immune dysregulation in autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation in pediatric patients. Biol Blood Marrow Transplant. 24(4):772\u2013778. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.782","journal-title":"Biol Blood Marrow Transplant."},{"key":"114_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/JBM.S190327","volume":"10","author":"W Barcellini","year":"2019","unstructured":"Barcellini W, Fattizzo B, Zaninoni A (2019) Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives. J Blood Med. 10:265\u2013278. https:\/\/doi.org\/10.2147\/JBM.S190327","journal-title":"J Blood Med."},{"issue":"1","key":"114_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1365-2141.2004.05138.x","volume":"127","author":"TA O\u2019Brien","year":"2004","unstructured":"O\u2019Brien TA, Eastlund T, Peters C, Neglia JP, Defor T, Ramsay NK et al (2004) Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol. 127(1):67\u201375. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05138.x","journal-title":"Br J Haematol."},{"issue":"2","key":"114_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.bbmt.2013.11.014","volume":"20","author":"M Faraci","year":"2014","unstructured":"Faraci M, Zecca M, Pillon M, Rovelli A, Menconi MC, Ripaldi M, Fagioli F, Rabusin M, Ziino O, Lanino E, Locatelli F, Daikeler T, Prete A, Italian Association of Paediatric Haematology and Oncology (2014) Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience. Biol Blood Marrow Transplant. 20(2):272\u2013278. https:\/\/doi.org\/10.1016\/j.bbmt.2013.11.014","journal-title":"Biol Blood Marrow Transplant."},{"key":"114_CR18","doi-asserted-by":"publisher","unstructured":"Wang M, Wang W, Abeywardane A, Adikarama M, McLornan D, Raj K, de Lavallade H, Devereux S, Mufti GJ, Pagliuca A, Potter VT, Mijovic A (2015) Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King\u2019s College Hospital. Biol Blood Marrow Transplant. 21(1):60\u201366. https:\/\/doi.org\/10.1016\/j.bbmt.2014.09.009","DOI":"10.1016\/j.bbmt.2014.09.009"},{"issue":"2","key":"114_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jaci.2020.04.053","volume":"146","author":"SH Lum","year":"2020","unstructured":"Lum SH, Selvarajah S, Deya-Martinez A, McNaughton P, Sobh A, Waugh S, Burton-Fanning S, Newton L, Gandy J, Nademi Z, Owens S, Williams E, Emonts M, Flood T, Cant A, Abinun M, Hambleton S, Gennery AR, Slatter M (2020) Outcome of autoimmune cytopenia after hematopoietic cell transplantation in primary immunodeficiency. J Allergy Clin Immunol. 146(2):406\u2013416. https:\/\/doi.org\/10.1016\/j.jaci.2020.04.053","journal-title":"J Allergy Clin Immunol."},{"key":"114_CR20","doi-asserted-by":"publisher","unstructured":"Mah\u00e9vas M, Michel M, Weill J-C, Reynaud C-A (2013) Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy. Front Immunol 4. https:\/\/doi.org\/10.3389\/fimmu.2013.00494","DOI":"10.3389\/fimmu.2013.00494"},{"key":"114_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fped.2019.00171","volume":"7","author":"JA Neely","year":"2019","unstructured":"Neely JA, Dvorak CC, Pantell MS, Melton A, Huang JN, Shimano KA (2019) Autoimmune cytopenias in pediatric hematopoietic cell transplant patients. Front Pediatr. 7:171. https:\/\/doi.org\/10.3389\/fped.2019.00171","journal-title":"Front Pediatr."},{"issue":"4","key":"114_CR22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1213\/ANE.0000000000001596","volume":"123","author":"JE Dalton","year":"2016","unstructured":"Dalton JE, Bolen SD, Mascha EJ (2016) Publication bias: the elephant in the review. Anesth Analg. 123(4):812\u2013813. https:\/\/doi.org\/10.1213\/ANE.0000000000001596","journal-title":"Anesth Analg."},{"issue":"10","key":"114_CR23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1080\/1744666X.2018.1521722","volume":"14","author":"W Barcellini","year":"2018","unstructured":"Barcellini W, Fattizzo B, Zaninoni A (2018) Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 14(10):857\u2013872. https:\/\/doi.org\/10.1080\/1744666X.2018.1521722","journal-title":"Expert Rev Clin Immunol."},{"issue":"2","key":"114_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211927","volume":"14","author":"H Nahi","year":"2019","unstructured":"Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, Ljungman P, Wagner AK, Alici E (2019) Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PLoS One. 14(2):e0211927. https:\/\/doi.org\/10.1371\/journal.pone.0211927","journal-title":"PLoS One."}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-021-00114-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-021-00114-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-021-00114-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T09:17:24Z","timestamp":1619687844000},"score":1,"resource":{"primary":{"URL":"https:\/\/molcellped.springeropen.com\/articles\/10.1186\/s40348-021-00114-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["114"],"URL":"https:\/\/doi.org\/10.1186\/s40348-021-00114-y","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"4 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects gave written informed consent in accordance with the Declaration of Helsinki. The immunological studies were performed according to the CCI Biomaterial Bank (IRB approval No. 282\/11).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All subjects gave written informed consent in accordance with the Declaration of Helsinki. The immunological studies were performed according to the CCI Biomaterial Bank (IRB approval No. 282\/11).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}